VC Roundup: October Brings Several New Venture Funds, Including Third Rock’s Fourth

Third Rock closed a $616m venture capital fund, exceeding the firm’s goal of $600m to fund newly formed biopharma companies, following Sofinnova and others with new VC and debt funds for early- to mid-stage life science companies. Also, five drug developers raised $256m in new VC cash.

Third Rock Ventures has raised its fourth and largest venture capital fund at $616m, joining at least three other groups that closed new life science-focused VC and debt funds in October for a total of $1.64bn.

More from Financing

More from Business